Showing results (121-130 of 146) with videos related to
Sort By:
Pageof 15
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.Blood Neoplasia|January 2, 2026
Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment responseAnna Maria Corsale, Mojtaba Shekarkar Azgomi, Emilia Gigliotta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.Blood Advances|May 12, 2023
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCLMaria Chiara Tisi, Riccardo Moia, Caterina Patti, et al.Frontiers in Oncology|July 10, 2023
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignanciesFrancesco Angotzi, Marco Petrella, Tamara Berno, et al.Haematologica|August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trialSara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalAntonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.Cancer|March 19, 2021
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practiceMarino Clavio, Elena Crisà, Maurizio Miglino, et al.Clinical Lymphoma, Myeloma & Leukemia|April 26, 2025
Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) ItalyLorenzo Cani, Maria Teresa Petrucci, Katia Mancuso, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trialAntonio Palumbo, Michele Cavo, Sara Bringhen, et al.Pageof 15